You are saying: "So anyone on this board care to be honest with me. You walk into your doc's office complaining of OA or RA. Doc says to you, I can prescribe you generic ibuprofen and famotidine which might set you back $30-40 a month, but requires popping 5 pills a day versus 3, OR I can prescribe you a combo pill that is no better for your condition, but will set you back over $700 a month".
If a doctor recommends a generic ibuprofen and famotidine blindly then he should lose his license to practice since different dosages may kill or injure patients.
In one of the past CC, CEO indicated that the company is working with POZN/AZN to expand Vimovo with different dosanges and combination as I understoos it. Remember that HZNP is a late stage drug developer. Again, as I undestand it, it may acquire drugs that have been approved in Europe or Japan and then get FDA approval here in US. I do not think anything else in its pipeline.
In my opinion, HZNP is taking lower risk to go after drugs that either approved by FDA or have high chance of approval. Drug development is very costly but very rewarding if a good one is developed.
It took years and a lot of money for HZNP to develop and to get approval of its 2 drugs. Now it is on new path to acquire and market developed drugs.
As I read some posts by Mike, Post, Med and others I can tell you the following
1- Management is working hard to create new strategy that is based on unique marketing, new products purchase and other things that have worked well so far.
2- As November of this year, debt with interest rate of 17% was dumped and replaced with a convertible note at interest rate of 5%.
3- As November, cash position was $78 M and zero debt (for not considering $150 convertible note as debt).
4- The company has predicted that it will be positive cash flow and positive income in 2014. Generating cash instead of burning it is a positive factor and lets the company hand open for purchasing new products and growing the company.
5- Company's CEO has indicated that HZNP will acquire more products to utilize its marketing system and strategy.
6- HZNP revenue has grown significantly quarter over quarter and will be up significantly in 2014.
There are a few more positive news line the stock was added to biotech index, insiders purchase...
S0, what else an investor wants for his money? An investor will be rewarded hugely compare to a small risk that he/she may take.
I don't think any small cap has this excellent balance sheet.
$9.5 book value
Receiveable much higher than payable.
A good size inventory.
A good size cash.
Probably, Forbes is short of revenue and it is doing whatever to get some money even if it is publishing some junk news, as long as some hedge funds willing to pay.
Junk media ands for profit media are misleading naive investors. Forb...has joined this group.
Just say China and ABT drops like a rock. Almost all junk medias have discovered this fact and use it daily.
I hope this will change after the earnings on Oct 16 since ABT has been milked enough for infant milk sale in China.
It does not matter if the article is related to ABT, but since it mentions China then ABT goes down.
All democrats should agree on repealing this stupid tax.
If a non-medical device takes 6 months to develop and costs $100k, a similar medical device takes at least 3 years and over $1 million to develop, test and get FDA approval.
Medical companies have low margins and taxing them is really stupid, stupid stupid. It does not matter who is doing it since it is stupid. I disappointed with democrats for only this act and they should correct this law.
I like Obama and democrats but why they want to tax medical devices. Do you know that medical device companies are the ones still here in US instead of China? May be they want to push them out of USA.
While there are many non-medical devices and drugs that should be taxed they go after something that damage economy and Peale in General.
This is the only thing that both parties should agree on.
Why medical devices in first place? Why not do it on cell phones and cars and many other things but leave medical devices alone since it is already very expensive ands time consuming for medical companies. to design something ands approve it with tons of FDA regulations.
ABT has a few of above technology in different fields that will drive a high growth in the future.
No wonder it spun off ABBV that will lose Humera in 2016. I think ABT will be way above ABBV by 2016.